VIRRX, INC

Basic Information

VIRRX, INC
1609 ADGERS WHARF DR
CHESTERFIELD, MO, 63017

Company Profile

n/a

Additional Details

Field Value
DUNS: 42417787
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. An HBV polymerase RNA binding assay suitable for inhibitor screening

    Amount: $260,910.00

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects over 350 million people worldwide and causes 6 ...

    SBIR Phase I 2009 Department of Health and Human Services
  2. Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs

    Amount: $222,658.00

    DESCRIPTION (provided by applicant): Human adenoviruses (Ads) are a significant problem in immunosuppressed humans, especially in children undergoing allogeneic stem cell transplants. About 20% of the ...

    STTR Phase I 2007 Department of Health and Human Services
  3. Animal Model for Adenovirus Oncolytic Vectors

    Amount: $182,459.00

    DESCRIPTION (provided by applicant): Adenovirus vectors have also been evaluated for their efficacy in treating cancer. As cancer is the second leading cause of death in the U.S. and current therapeut ...

    STTR Phase I 2004 Department of Health and Human Services
  4. Anti-Cancer Vectors that Express TRAIL

    Amount: $247,645.00

    DESCRIPTION (provided by applicant): We have developed replication-competent oncolytic adenovirus (Ad) vectors for cancer gene therapy that are designed to spread rapidly from cell to cell by virtu ...

    SBIR Phase I 2004 Department of Health and Human Services
  5. Regulatable expression of TRAIL and viral oncolysis

    Amount: $161,875.00

    DESCRIPTION (provided by applicant): We have constructed an oncolytic adenovirus vector named "KD3" that replicates selectively in cancer cells as opposed to normal cells because of a mutation in the ...

    STTR Phase I 2004 Department of Health and Human Services
  6. Chaperone-based tumor therapy delivered by viral vectors

    Amount: $169,167.00

    DESCRIPTION (provided by applicant): The efficacy of molecular chaperones as adjuvants for the induction of anti-tumor immunity has been demonstrated in many laboratories over the last two decades. S ...

    STTR Phase I 2003 Department of Health and Human Services
  7. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    Amount: $0.00

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a ...

    STTR Phase I 2002 Department of Health and Human Services
  8. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    Amount: $711,039.00

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a ...

    STTR Phase II 2002 Department of Health and Human Services
  9. DEVELOPMENT OF A VIRUS VECTOR VACCINE AGAINST ANTHRAX

    Amount: $140,710.00

    DESCRIPTION (provided by applicant): The events on and following September 11, 2001 have revealed our nation's vulnerability to terrorist attacks. Although much talked about during the past decade, t ...

    SBIR Phase I 2002 Department of Health and Human Services
  10. ADENOVIRUS REPLICATION COMPETENT ANTICANCER VECTOR

    Amount: $100,000.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government